Corline Biomedical AB reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 8.58 million compared to SEK 7.2 million a year ago. Revenue was SEK 8.6 million compared to SEK 7.31 million a year ago. Net loss was SEK 2.41 million compared to net income of SEK 0.875 million a year ago. Basic loss per share from continuing operations was SEK 0.11 compared to basic earnings per share from continuing operations of SEK 0.04 a year ago. Diluted loss per share from continuing operations was SEK 0.11 compared to diluted earnings per share from continuing operations of SEK 0.04 a year ago.
For the six months, sales was SEK 18.78 million compared to SEK 11.62 million a year ago. Revenue was SEK 18.81 million compared to SEK 11.83 million a year ago. Net loss was SEK 1.39 million compared to net income of SEK 0.023 million a year ago. Basic loss per share from continuing operations was SEK 0.06. Diluted loss per share from continuing operations was SEK 0.06.